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Abstract
Background: A device was devised which aimed to reduce the time and expertise required to perform
sonoporation on adherent cell cultures. This prototype device was used to examine the superficial effect of bath
temperature on sonoporation efficacy.
Methods: The prototype device consisted of six ultrasound transducers affixed beneath an Opticell stage. Six
transducers with nominal diameters of 20 mm were constructed and the acoustic field of each was characterized
using hydrophone scanning. A near field treatment plane was chosen for each transducer to minimize field
heterogeneity in the near field.
Cervical cancer-derived SiHa cells were exposed to nine different treatments in the presence of plasmid
DNA-expressing green fluorescent protein (GFP). Ultrasound treatment with Definity ultrasound contrast agent
(US+UCA) present, ultrasound treatment without contrast agent present (US), and a sham ultrasound treatment in the
presence of ultrasound contrast agent (CA) were each performed at bath temperatures of 37, 39.5, and 42 °C. Each
treatment was performed in biological triplicate. GFP expression and PARP expression following treatment were
measured using fluorescent microscopy and digital image processing. Cell detachment was measured using phase
contrast microscopy before and after treatment.
Results: Mean (± s.d.) transfection rates for the US+UCA treatment were 5.4(±0.92), 5.8(±1.3), and 5.3(±1.1) % at 37,
39.5, and 42 °C, respectively. GFP expression and cell detachment were both significantly affected by the presence of
ultrasound contrast agent (p < 0.001, p < 0.001). Neither GFP expression, PARP expression, or detachment differed
significantly between bath temperatures.
Conclusions: Bath temperature did not impact the efficacy of sonoporation treatment on SiHa cells in vitro. The
prototype device was found to be suitable for performing sonoporation on adherent cell cultures and will reduce the
time and expertise required for conducting sonoporation experiments on adherent cell cultures in the future.
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Background
Sonoporation is a process in which ultrasound exposure
can induce a transient increase in the permeability of cell
membranes. This process has been shown to be highly
dependent on the presence of cavitation nuclei [1–3]. In
practice, clinically approved ultrasound contrast agents,
comprised of microscale inert gas bubbles (“microbub-
bles”) often having lipid, polymer, or protein shells, are
added to cell media to serve as cavitation nuclei during
ultrasound exposure.
Microbubble cavitation is known to induce a number
of biophysical effects. At low acoustic intensities, sta-
ble cavitation has been shown to induce shear stress on
the cell membrane by the generation of rapid flow in
the surrounding medium, referred to as “microstreaming”
[4–6]. In [4], the authors captured high-speed images
of oscillating microbubbles pushing and pulling on the
cell membrane when in close proximity, an interaction
which correlated with increased uptake of propidium
iodide. At higher acoustic pressures, inertial cavitation
can occur, resulting in the formation of shock waves as
well as “microjets” in the presence of a relatively rigid
cell membrane [7, 8]. The stresses on the cell membrane
due to cavitation can result in physical damage to the
cell membrane allowing for the passive diffusion of agents
across [4, 9].
In addition to physical disruption of the cell membrane,
cavitation has been shown to provoke other biological
effects. For example, there is evidence that endocytosis
plays a role in the uptake of agents during sonoporation.
In [9], the authors observed that following ultrasound-
mediated uptake of dextrans into primary endothelial
cells, the smaller dextrans used (4.4 and 70 kDa) were
homogeneously distributed in the cytosol whereas the
larger dextrans used (155 and 500 kDa) were heteroge-
neously distributed and encapsulated by endocytotic vesi-
cles. The authors then examined the effect of a number
of endocytosis-inhibiting treatments and observed signif-
icant decreases in uptake of dextrans from sonoporation.
Though decreases were seen in the uptake of smaller dex-
trans, the decrease in uptake of the larger dextrans was
much more pronounced.
Sonoporation is of particular interest to those in the
field of cancer research as it promises to provide a non-
viral means for targeted drug delivery and gene ther-
apy. High-risk human papillomavirus (HPV) infection is
strongly associated with the development of cervical can-
cer, the second most common cancer affecting women
worldwide [10]. Currently, standard treatment of cervi-
cal cancer includes radiation therapy and surgery, each
having their own undesirable side effects. Ultrasound-
mediated delivery of therapeutic macromolecules which
target the oncoproteins encoded by the HPV DNA (e.g.,
plasmid DNA [2, 11] and small interfering RNA [12, 13])
may provide a minimally invasive alternative to current
treatment options. In vitro studies on cell cultures are
an essential part of discovery and testing of therapeutic
agents which can be delivered using this process.
There have been a few experimental setups described
in the literature for performing sonoporation in vitro on
adherent cell cultures. The cells are typically adhered
to either a well plate, Petri dish [13–17], or the inner
membrane of an Opticell cell culture chamber (Thermo
Scientific Nunc, Waltham, MA, USA) [2, 12, 18–23]. The
use of well plates and Petri dishes located at the surface
of the ultrasound bath is problematic since the acoustic
conditions at the media-air interface may not necessarily
be known due to the possibility of reflection and standing
wave formation [14]. In [13], the authors use an elaborate
setup to eliminate the media-air interface at the well plate
which involves placing a second water bath on the far side
of the well plate with respect to the acoustic source.
The Opticell cell culture chambers consist of two thin,
parallel, gas-permeable, cell culture-treated polystyrene
membranes. These chambers allow for adherent cell cul-
ture with sterile media and appropriate oxygen and car-
bon dioxide levels, while facilitating ultrasound exposure
through a minimally reflective surface [2]. Their abil-
ity to be fully submerged in the ultrasound bath allows
for an acoustic absorber to be placed in the acoustic far
field, reducing the effects of reflection and standing wave
formation.
Due to the growth area of an Opticell (50 cm2), mul-
tiple acoustic exposures are often performed across the
cell culture area with a single transducer and the aid of a
positioning system [12, 15, 18, 19, 21]. In order to ensure
consistent acoustic exposure, the cell culture, position-
ing system, and transducer must be well aligned. Our
group has used an experimental setup consisting a three-
axis, computer-controlled micropositioning system in a
large (approximately 200 L) water tank (UMS2; Preci-
sion Acoustics, Dorsetshire, UK) for sonoporation studies
[12, 18, 24]. Aligning the cell culture and configuring
the experiment software was a long and involved pro-
cess, requiring experience with software programming,
electronics, and acoustics. For instance, the positions of
three known points on the cell culture stage needed to be
localized by pulse-echo and scanning techniques in order
to determine its orientation. Once the cell culture stage
was aligned and the software was configured, each expo-
sure was performed sequentially, requiring time between
each target for the transducer to travel and rest. The time
required for the large water bath to be filled, degassed,
heated to a biologically relevant temperature, and emptied
also consumed a large portion of the experiment day.
Here, a device for sonoporation of adherent cell cul-
tures is presented. This device aims to reduce the time and
expertise required for experiment setup with respect to
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our previous setup. The device was constructed and char-
acterized before being experimentally validated. Addi-
tionally, as part of a preliminary study of the effects of
temperature on sonoporation, this device underwent test-
ing at bath temperatures 37, 39.5, and 42 °C represent-
ing a temperature range from biological temperature to
hyperthermia. The rationale of studying the effect of tem-
perature was to foresee a potential synergistic effect of
mild thermal effects in the transfection efficiency, which




A sonoporation device was devised using an array of
ultrasound transducers and a cell culture stage designed
for use with the Opticell cell culture system (Fig. 1).
The transducer array consisted of six air-backed trans-
ducers, each having a square (26 × 26 mm) housing,
25 mm tall. The transducer housings were fabricated from
ABS (acrylonitrile-butadiene-styrene) plastic (Makerbot
Industries, New York, NY, USA) using a desktop 3D
printer (Makerbot Replicator; Makerbot Industries, New
York, NY, USA). Each transducer featured a flat, circular
piezoelectric crystal with a nominal diameter of 20 mm
(DL-47; Del Piezo Specialties, LLC, West Palm Beach, FL,
USA). The device was designed such that the transducer
array was affixed beneath the Opticell stage in order to
maintain the distance between the transducers and the
target cells between experiments, greatly minimizing the
time and training requirements for setting up the acoustic
conditions. The cell culture stage, transducer frame, and
body frame were also fabricated with ABS via 3D printing.
Each transducer was electrically matched to 50  at its
operating frequency (1 MHz) using an external low-pass
L-type matching circuit with the aid of a network analyzer
(HP 8127ES; Hewlett Packard, Palo Alto, CA, USA).
The device was chosen to operate in the near field
of the transducers in order to minimize its size. The
acoustic intensity profile of each transducer was obtained
using the planar scanning method using a calibrated nee-
dle hydrophone (0.2 mm, SN1426; Precision Acoustics,
Dorsetshire, UK) and a motorized micropositioning sys-
tem (UMS2; Precision Acoustics, Dorsetshire, UK) at low
acoustic pressures. The acoustic intensity down the center
of the beam path was obtained from 8 to 70 mm (Fig. 2).
A range of 10–20 mm was explored for a treatment plane
as a trade-off between peak intensity and treatment dis-
tance (homogeneity). Slices perpendicular to the beam
path (10.5× 10.5 mm, = 0.7 mm) were obtained on this
range and characterized for field homogeneity (Fig. 3a).
Homogeneity was quantified as the standard deviation
of the pressure over the circular area encompassed by
the planar scan, centered with the acoustic axis (Fig. 3b).
The distance at which the minimum standard deviation
occurred was chosen as the optimal treatment distance for
the transducer (Fig. 3c). This distance was determined for
each transducer. Finally, on each optimal plane, a point of
approximately 90 % relative intensity was chosen in order
to determine the electrical power required to produce
the desired peak-negative pressure. The input electrical
voltage for each transducer was adjusted to achieve the
acoustic power required for the ultrasound exposures.
One of the six transducers was measured over a wider
plane (40 × 40 mm,  = 0.7 mm) to examine the amount
of cross-talk from one transducer to the treatment area
Fig. 1 A computer rendering (exploded) of the device illustrating the different parts. A computer rendering (exploded) of the device illustrating the
different parts. The transducer array body and cell culture stage are affixed to the body frame by a set of screws. The Opticell is press-fit into the
Opticell stage before treatment by the operator and can easily be removed by hand
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Fig. 2 Acoustic intensity along the acoustic axis of a select transducer. The acoustic intensity measured down the center of the acoustic axis (z) from
z = 8 mm to z = 70 mm in steps of z = 0.1 mm for 8–13 mm and z = 0.7 mm for 13–70 mm
of another (Fig. 4) and was found to be sufficiently low
(< −16 dB).
Experimental groups
Experiments were divided into nine groups consisting
of three different treatments and three different tem-
peratures. Cells either underwent a sonoporation treat-
ment (US+UCA) which exposed the cells to high-intensity
ultrasound with UCA present, an ultrasound treatment
(US) which exposed the cells to high-intensity ultrasound
without UCA present, or a sham ultrasound treatment
(UCA) which used zero acoustic power (amplifier turned
off ) with UCA present. Each of these three treatments
was performed at 37, 39.5, and 42 °C with plasmid DNA
present. These three temperatures represent a tempera-
ture range from biological temperature to hyperthermia.
All nine experimental groups were repeated three times.
Ultrasound exposure
The ultrasound generation parameters used in the exper-
imental validation were adopted from previous studies by
our group [12, 18] in order to compare its relative perfor-
mance with our previous system. These parameters were
originally chosen based on preliminary work by our own
group [24]. Pulsed ultrasound at 1 MHz delivered at a
peak-negative pressure of 0.7 MPa to the cell culture in
bursts of 30 cycles every 625 μs (4.8 % duty cycle; 1.6 kHz
pulse repetition frequency) for a total time of 30 s.
The ultrasound signal for performing both character-
ization and sonoporation was generated using a wave-
form generator (33522; Agilent Technologies Canada Inc.,
Mississauga, Ontario, Canada) and amplified using a
linear, radio-frequency power amplifier (A150; E&I,
Rochester, NY, USA). The power during sonication was
monitored using an in-line directional coupler (C5685-10;
Werlatone Inc., Patterson, NY, USA) and power meter
(2× N8482H sensors and N1914A meter; Agilent
Technologies Canada Inc.). This setup allowed for the
excitation of one transducer at a time during experiments.
Hence, each treatment area of the cell culture chamber
was treated sequentially in random order. An additional
period of 30 s after each exposure was added to allow the
operator to switch to the next transducer in the array.
Cell culture
Cervical cancer-derived SiHa cells (ATCC HTB-35, Man-
assas, VA, USA) were used in this study. Such cells contain
1–2 genome copies of HPV type 16 per cell [25]. The
cells were maintained in 75-cm2 flasks containing Dul-
becco’s Modified Eagle Medium (DMEM; Sigma-Aldrich,
Oakville, Ontario, Canada) supplemented with 10 % heat-
inactivated fetal bovine serum (FBS; Hyclone Laboratories
Inc., Logan, UT, USA), 100 U of penicillin, 100 μg of
streptomycin, and 0.25 μg amphotericin B per mL (antibi-
otic/antimycotic; Gibco, Grand Island, NY, USA) at 37 °C
and 5 % CO2. The cells were passaged to maintain 70–
80 % confluency. Twenty-four hours before treatment, the
cells were seeded (0.6 × 106) into an Opticell chamber to
allow the cells to adhere to the inside membrane.
Immediately following treatment, the Opticell was
removed from the ultrasound bath, wiped with 70 %
ethanol, and returned to the incubator where the cells
were incubated at 37 °C. After 2 h, 1.1 mL of serum-free
media was removed from the Opticell and the remaining
media was supplemented with 1 mL of FBS and 100 μL of
antibiotic/antimycotic, returning the cells to their original
media composition. The cells were then incubated for an
additional 24 h to allow for GFP expression by the cells.
Plasmid DNA
Plasmid DNA (pDNA) expressing green fluorescent pro-
tein (GFP) was used to quantify successful transfection.
To produce copies of the plasmid, chemically competent
NEB 5-αF’Iq Escherichia coli bacteria (New England Bio
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Fig. 3 Treatment profile heterogeneity. a The measured acoustic profile of a 10.5 × 10.5 mm plane perpendicular to the beam path for one of the
transducers where x = y = 0.7 mm < 0.5λ. b The mask used to select a circular region for calculating homogeneity in a, where black represents
the selected area. c The measured “heterogeneity” of each slice at different points along the acoustic axis from 13 to 17 mm for one of the
transducers, showing a local minimum at z = 16 mm. This point was chosen as the optimal near field treatment distance for this transducer
Labs Inc., Ipswich, MA, USA) were transformed with
6.3-kb Omicslink pReceiver-M03 plasmid containing the
GFP complementary DNA (Genecopia Inc., Rockville,
MD, USA). Plasmid DNA was extracted and purified with
EndoFree Plasmid Maxi Purification kits (Qiagen Inc.,
Toronto, Ontario, Canada) to minimize bacterial endo-
toxin levels. Prior to treatment, the cells were washed with
serum- and antibiotic-free DMEM and incubated with
250 μg of plasmid DNA in 10 mL of serum and antibiotic-
free DMEM for 15 min at 37 °C and 5 % CO2 to allow the
plasmid DNA to diffuse within the media.
Ultrasound contrast agent
Definity ultrasound contrast agent (Lantheus Medical
Imaging, North Billerica, MA, USA), consisting of bub-
bles of a perflutren gas core and lipid shell, was used
to introduce cavitation nuclei during the sonoporation
process. The contrast agent was activated according to
the manufacturer’s recommended procedures (Vialmix,
Lantheus Medical Imaging, North Billerica, MA, USA).
For those experimental groups which included contrast
agent, 33 μL of activated contrast agent was added to
the 10-mL media in the Opticell chamber 1 min before
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Fig. 4 Device cross-talk in array. A wide scan (40 × 40 mm,  = 0.7 mm) of one of the transducers at its treatment distance taken to examine the
field intensity near surrounding transducers in the array. Denoted in white are the −6 (solid) and −18 dB (dashed) contours and in black are an
approximation of the orthographic projection of the source transducer (dashed) and the approximate distance to the edge of a neighbouring
transducer (dotted). The −18 dB contour shows that the intensity at the edge of neighbouring transducers is low (< −16 dB)
transferring to the water bath, giving a final volume con-
centration of 0.33 %. Nominally, activated Definity con-
tains 1.2× 1010 microbubbles per milliliter corresponding
to a microbubble-cell ratio of 660:1. During treatment, the
Opticell was placed horizontally in the cell culture stage
with the cells on the upper-most membrane, allowing for
the microbubbles to rise and rest against the cells during
insonation.
Bath conditioning and heat treatment
Experiments were conducted in a bath of deionized,
degassed water (Fig. 5). The bath water was initially cir-
culated through a degassing system until the detectable
level of dissolved oxygen was <1.0 ppm (407510A; Extech
Instruments Corporation, Nashua, NH, USA). The water
was also circulated through an in-line water heater (Model
210; PolyScience, Niles, IL, USA) to raise it to the
desired temperature. The heater continued to circulate
water throughout the duration of the experiment in order
to maintain the temperature of the bath. The compact
dimensions of the device allowed for experiments to be
performed in a small water tank (a 26 L tote) reducing the
time consumed by filling and emptying the tank as well as
degassing and heating the water bath.
The cells and medium in the Opticell chamber were
given 1 min to equalize with the temperature of the sur-
rounding bath before starting the ultrasound exposure.
This value was determined experimentally by measur-
ing the time that water in an Opticell chamber took to
rise from the temperature of the incubator (37 °C) to the
maximum bath temperature tested (42 °C). Due to the
large ratio between the surface area and the volume of
the Opticell, the average time for this rise to occur was
approximately 40 s, which was rounded up to 1 min to
ensure the temperature had stabilized.
Considering the initial temperature equalization time
and subsequent treatment time, each Opticell was sub-
merged in the bath for a total of 7 min.
Quantification of transfection and viability
Transfection efficiency and viability were quantified using
microscopy and image processing. Cell imaging was
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Fig. 5 Sonoporation experimental setup schematic. Sonoporation setup featuring a transducer array below an Opticell chamber. Beyond the cell
culture is an ultrasound-absorbentmaterial (Aptiflex; Precision Acoustics, Dorsetshire, UK) intended to reduce reflection and standing wave formation
performed using a Zeiss Axiovert 200 inverted micro-
scope (Carl Zeiss Canada Ltd., North York, Ontario,
Canada) and an LD A-Plan 10×/0.25 Ph1 objective for
a total magnification of 100×. A 12-bit CCD camera
(Q Imaging, Surrey, British Columbia, Canada) was used
to capture the microscope images to digital format for
processing.
Cell loss (detachment) was evaluated by imaging the
cell cultures in three random spots per exposure area (18
total per replicate) 15 min before and 2 h after treat-
ment with phase contrast imaging. Each cell was manually
identified by applying an identifying marker (a dot) over
the digital phase contrast images and subsequently cre-
ating a new image containing only the dots on a blank
background. These marked images were then used to
automatically obtain cell counts per field of view using
CellProfiler software (2.0.0) [26]. The cell counts per field
of view were averaged per replicate for analysis. The cell
loss for each replicate was evaluated as the relative change
in the average cell count 15 min before and 2 h after
treatment where a negative relative change represented
a drop in cell count. It was assumed that any cells that
detached were non-viable. The viability of the remaining
cells was determined by visualizing cleaved poly (ADP-
ribose) polymerase (PARP), an early apoptotic indicator,
24 h after treatment.
Twenty-four hours following treatment, the Opticell
membrane with the adhered cells was removed and the
cells were fixed with a 4 % solution of paraformalde-
hyde (PFA) in phosphate-buffered saline (PBS). The fixed
cells were permeabilized with a 0.1 % solution of Triton-
X in PBS for 5 min and rinsed with PBS. The cells
were then blocked with a 1 % solution of bovine serum
albumin (BSA) in PBS for 10 min at room tempera-
ture. Since the fluorescent signal produced by the GFP
was quenched by the PFA fixing, a goat polyclonal anti-
GFP antibody (ab5450; Abcam Inc., Toronto, Ontario,
Canada) was applied at 1:1000 in 1 % BSA/PBS to bind
to the GFP protein produced by transfected plasmid.
A green fluorescent AlexaFluor 488 donkey anti-goat
secondary antibody (LifeTechnologies Inc., Burlington,
Ontario, Canada) was applied at 1:400 in 1 % BSA/PBS to
visualize the antibodies bound to the GFP. A monoclonal
mouse anti-cleaved PARP antibody (ab1103315; Abcam
Inc., Toronto, Ontario, Canada) was applied at 1:760 in 1 %
BSA/PBS and visualized with a secondary red fluorescent
Alexa Fluor 594 donkey anti-mouse antibody (LifeTech-
nologies Inc., Burlington, Ontario, Canada) applied at
1:800 in 1 % BSA/PBS. The cells were counter-stained
with 4’,6-diamidino-2-phenylindole (DAPI) to identify the
nuclei of the cells before being mounted onto slides for
imaging. DAPI was already incorporated directly into
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the medium use to mount the cells on the Opticell
membranes.
The stained cells were imaged in five random spots per
treatment area using green, blue, and red fluorescence fil-
ters. One of the six treatment areas was used as a staining
control, limiting the total available fields of view for analy-
sis to 25 per replicate. Each field of view was captured for
each of the three stains (Figs. 6 and 7).
Object segmentation was performed on the fluorescent
microscopy images using CellProfiler (2.0.0) [26]. Two
types of “objects” (independent areas of the image) were
extracted in each field of view: (1) the nuclei objects,
extracted from the blue DAPI images; and (2) cell bound-
ary objects, extracted using a combination of the blue
DAPI and green GFP secondary antibody images. These
objects were extracted using an Ostu-global segmenta-
tion method with minimization of weighted variance. The
extracted objects represented areas of the image occupied
by individual nuclei (nuclei objects) or cells (cell bound-
ary objects). Consequently, the background of the image
was identifiable, based on the area not occupied by any
object.
For an object to be considered positive for either trans-
fection (green) or apoptosis (red), the image intensity
inside the object should be significantly higher than the
image intensity of the background. Thus, the following
criterion was used to detect positive objects:
I¯obj ≥ I¯bg + nσbg (1)
where I¯obj is the mean image intensity within an object,
I¯bg is the mean intensity of the background, σbg is the
standard deviation of the background intensity, and n is
the number of standard deviations that the mean object
intensity must be from the mean background intensity for
the object to be considered positive. In [12], a value of
n = 2 was used with this method. This threshold was
increased to n = 3 in this work. A cell was considered
transfected if it met this criterion using the green GFP
secondary antibody images. Cell boundary objects were
used in transfection detection since the GFP secondary
antibody signal would be observed in both the cytoplasm
and nucleus of each positive cell. This same criterion was
used for detecting cells positive for apoptosis using the
intensity of the red cleaved PARP secondary antibody
images. Since the cleaved PARP secondary antibody sig-
nal would be observed in the nucleus of each positive cell,
the nuclei objects were used. The number of objects pos-
itive for transfection and apoptosis were counted relative
to the number of cells in the image. The fraction of pos-
itive objects within each field of view was averaged per
replicate for statistical analysis.
Statistical analysis
Statistical analysis was performed using R (2.15.2) [27].
Observations were tested for normality using the Shapiro-
Wilk test and homogeneity of variance using Bartlett’s
test. A two-way ANOVA was used to test the effects on
parametric data. A post hoc Tukey’s HSD (honestly sig-
nificant differences) test was performed on significant
effects. For non-parametric data, the Kruskal-Wallis rank
sum test was used to test effects and a post hoc pair-
wise Wilcoxon rank sum test was performed for signifi-




Transfection rates for each experimental group are shown
in Fig. 8. For temperatures of 37, 39.5, and 42 °C,
the average (±s.d.) percentages of transfected cells for
the sonoporation treatment (US+UCA) were 5.4(±0.92),
5.8(± 1.3), and 5.3(±1.1) %, respectively; the percent-
ages of transfected cells for the ultrasound treatment (US)
were 0.66(±0.38), 1.1(±0.46), and 0.57(±0.26) %, respec-
tively; and the percentages of transfected cells for the
sham treatment (UCA) were 0.50(±0.22), 0.73(±0.24),
and 1.3(±0.53) %, respectively.
Treatment was observed to have a significant effect
on transfection efficiency (p < 0.001). Post hoc analy-
sis showed that the cells that received the sonoporation
treatment (US+UCA) had a significantly higher expres-
sion of GFP over the control treatments (p < 0.001 for
a b c
Fig. 6 Fluorescent microscopy example showing transfected cells. An example field of view from the US+UCA group showing a DAPI (nuclei), b GFP
antibody (transfected), and c DAPI and GFP antibody fluorescence overlaid.White line denotes 100 μm
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Fig. 7 Fluorescent microscopy example showing apoptotic cells. An example field of view from the US+UCA group showing a DAPI (nuclei), b
cleaved PARP antibody (apoptosis), and c DAPI and cleaved PARP antibody fluorescence overlaid.White line denotes 100 μm
both). Transfection efficiency was not observed to be sig-
nificantly affected by bath temperature (p = 0.564) or
treatment-temperature interaction effects (p = 0.684).
Cell viability
Rates of cell loss following treatment for each experimen-
tal group are shown in Fig. 9. For temperatures of 37,
39.5, and 42 °C, the cell losses for the US+UCA treatment
group were −31(±3.4), −32(±13), and −34(±17) %, res-
pectively; cell losses for the US treatment group
were −6.7(±7.9), −9.1(±8.3), and −18(±5.9) %,
respectively; and cell losses for the UCA treatment
group were −5.6(±7.4), −2.8(±7.9), and −2.2(±12.2) %,
respectively.
Cell loss was not significantly affected by tempera-
ture (p = 0.661) or treatment-temperature mixed effects
(p = 0.778). However, cell loss was found to be
significantly affected by treatment (p < 0.001). Post hoc
Fig. 8 Rates of transfection for each treatment at each temperature.
Transfection rates for each treatment and temperature tested. Post
hoc analysis showed that the US+UCA treatment group had
significantly higher percentage of transfected cells over the other two
treatment groups independent of temperature (p < 0.001 for both).
There was no significant effect observed in transfection rates with
temperature or treatment-temperature mixed effects. Error bars
represent ± s.d. (n = 3 per group)
analysis showed that US+UCA treatment had significantly
higher levels of cell loss over the US and UCA treatment
groups (p = 0.0076 and p = 0.0002, respectively).
Rates of apoptosis for each experimental group are
shown in Fig. 10. For temperatures of 37, 39.5, and
42 °C, the ratios of apoptotic cells for the US+UCA group
were 0.34(±0.15), 0.22(±0.08), and 0.41(±0.2) %, respec-
tively; the ratios of apoptotic cells for the US group were
0.31(±0.25), 0.22(±0.10), and 0.23(±0.11) %, respectively;
and the ratios of apoptotic cells for the UCA group were
0.18(±0.17), 0.32(± 0.08), and 0.21(±0.10) %, respectively.
The percentage of remaining cells indicating apoptosis
24 h following treatment was low (<0.75 %) and was not
significantly affected by treatment (p = 0.437), temper-
ature (p = 0.896), or treatment-temperature interaction
effects (p = 0.371).
Discussion
The sonoporation device presented here was able to
induce significantly higher transfection of GFP plasmid
DNA over the control groups 24 h following treatment.
This device was chosen to operate under the similar exci-
tation parameters as our previous system in order to com-
pare its relative performance. In [18], our previous system
produced a transfection efficiency of 6(±2) % with a cell
detachment rate of −47(±32) % using similar excitation
parameters, plasmid, and cell line. At 37 °C, the system
presented here was able to achieve a transfection rate of
5.4(±0.92) % with a cell detachment rate of −31(±3.4) %.
The rates seen here are slightly lower than those seen with
our previous system. As transfection has been noted to be
dependent on the acoustic pressure [1, 3], a lower rate of
transfection may be due to the use of 0.7 MPa here which
is lower than the 1 MPa used in [18].
To the best of our knowledge, there are no other groups
performing sonoporation on SiHa cells in particular. Fur-
thermore, the acoustic excitation parameters, acoustic
conditions, and impermeable agent used vary across the
literature, making comparisons between different stud-
ies difficult. There are a number of studies on adherent
cell cultures which exhibit similar rates of transfection
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Fig. 9 Rates of cell loss for each treatment at each temperature. Relative change in cell count following treatment (+2 h) for each treatment and
temperature. Post hoc analysis showed US+UCA treatment has significantly higher cell loss over the other two treatments (p < 0.001 for both).
There was no significant effect observed in transfection rates with temperature or treatment-temperature mixed effects. Error bars represent ± s.d.
(n = 3 per group)
albeit under different acoustic and experimental condi-
tions. For example, in [2], sonoporation using 1 MHz
of pulsed ultrasound was examined under a number of
different excitation parameters using a near field setup.
The authors found that sonoporation at their optimal
parameters (1 MHz, 0.25 MPa peak-negative pressure,
4 % duty cycle, 1 kHz PRF, 10 s exposure, 4 % SonoVue
UCA concentration) was able to deliver plasmid DNA
with an efficiency of ∼4 % to Chinese hamster ovary
(CHO) cells with ∼90 % cell viability. A direct compar-
ison to more established transfection methods such as
chemical action was not performed for simplicity rea-
sons. Transfection efficiency with chemical methods also
depend on multiple factors including cell membrane con-
ditions, nucleic acid/chemical ratio, among others, thus
affecting considerably the transfection efficiency in func-
tion of the cell line [28]. For example, non-published data
from our group on chemical transfection on NIKS cells
(which are also adherent, epithelial cells like SiHa, but
HPV negative) and a concentration of 0.5 μg/mL plasmid
DNA showed transfection efficiencies ranging from 3.4
to 14 %, depending on the experimental replicate, which
indicates a strong variability depending on the mentioned
conditions.
The presence of UCA during ultrasound exposure not
only had a significant effect on transfection but it also
Fig. 10 Rates of apoptosis for each treatment at each temperature. The ratio of apoptotic cells for each treatment and temperature. Apoptosis rates
were low (<0.75 %) across all treatments and temperatures. No significant effects on apoptosis rates were observed with treatment, temperature, or
mixed effects. Error bars represent ± s.d. (n = 3 per group)
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appeared to have a significant effect on cell detachment.
There have been a number of reports of high levels of cell
detachment among the same order as seen here [2, 19, 29].
The level of cell detachment due to ultrasound exposure
alone (US group) was on the same order as the sham treat-
ment (UCA group) at 37 °C. Since the US+UCA group had
significantly higher cell detachment over US alone and
UCA alone, microbubble cavitation may be facilitating
cell detachment. In [30], high-pressure shock waves were
used to induce cavitation in an adherent cell culture. Using
high-speed imaging, the authors found that cell detach-
ment only occurred when cavitation activity was present.
The reason for this, they suggested, was that the flow due
to the cavitating bubble near the rigid substrate generated
a shear force large enough to remove the cells from the
substrate. Though the rarefactional pressure of the shock
waves in [30] was large enough to induce cavitation with-
out UCA present, a similar effect may have occurred at
a lower pressure amplitude here due to the presence of
the UCA.
The preliminary study of temperature on sonoporation
efficacy resulted in no observable, significant, net-positive
effect under our experimental conditions with increased
bath temperature. There are many factors involved in the
sonoporation process which have temperature-dependent
qualities which, together, may affect its efficacy. For
instance, the cavitation of microbubbles is an important
factor. Microbubble properties such as size distribution
and stability have been shown to be affected by tempera-
ture [31, 32]. In [32], the mean microbubble diameter for
SonoVue UCA (phospholipid-shell) was seen to increase
with temperature and, after a few minutes, dropped
abruptly. The growth of the microbubbles was thought
to be occurring due to the gas expansion of the bubbles
as well as the reduced surface tension of the shell. The
phase transition temperature of the shell of SonoVue UCA
has been noted to be around 40 °C [31]. The decreas-
ing stability with time was attributed to the possibility of
a phase change of the shell since a similar drop was not
observed at 37 °C. Though the UCA used here (Definity) is
not identical, there may be similarities in its temperature-
dependent behavior. That is, the higher temperatures may
have affected both the microbubble size and stability of
the Definity UCA during treatment. Here, the total treat-
ment time was 7 min whereas the abrupt drop in SonoVue
population observed in [32] occurred around 6 min. It
may be the case that during the sequential insonations
that the properties of the microbubbles changed between
the exposures, affecting the average per-replicate trans-
fection efficiency and cell detachment at the elevated
temperatures.
Temperature-dependent qualities of the cell membrane
such as membrane fluidity have been seen to affect sono-
poration efficacy as well. In [33], prostate cancer-derived
PC-3 cells treated with a heat treatment (44 °C, 1-min
equalization) showed a 15-fold increase in the rate of
transfection from sonoporation treatment over 37 °C. This
is in contrast to the effect observed here. The authors
attributed the increase in transfection to an increase in
membrane fluidity as the effect was similar to lidocaine
treatment, a substance known to increase membrane flu-
idity. The effect of temporal microbubble size and stability
in [33] was likely minimal due to the short per-replicate
insonations (1 min).
The magnitude and homogeneity of the acoustic field
may have been affected at the fixed treatment distance
due to a change in the speed of sound of the water bath
at higher temperatures. Due to the device’s operation in
the near field region, this effect would likely be more pro-
nounced than if the treatment distances were closer to the
near-far field transition distance (∼45mm in Fig. 2). How-
ever, the change in speed of sound due to temperature
from 37 to 42 °C is a relatively small change, approximately
0.53 % (1524 m/s v. 1532 m/s [34]).
In order to come to a conclusion on the effect of temper-
ature on sonoporation efficacy on SiHa cells, these many
factors must be subject to future study.
The sonoporation device, as it is presented here, only
addresses a subset of the issues which impede the routine
use of our previous system. The driving of the transduc-
ers still requires generalized electrical equipment such
as an arbitrary waveform generator and an amplifier as
well as manual switching and setup of these devices.
Also, the current version lacks of a cavitation detec-
tor that can be used to better correlate bubble activity
and transfection effects. Future version of the device
will incorporate a small factor 6-channel amplifier and
a cavitation detector, which can be easily incorporated
in the current design. Nevertheless, the device addresses
two important aspects of the previous system’s setup.
First, the device currently eliminates the time and train-
ing required for setting up the acoustic conditions for
the experiment. The fixed positions of the transducers
need to be set once during construction, after charac-
terization. Once the transducers are in a fixed position,
the acoustic conditions are maintained between experi-
ment days without intervention by the operator. Second,
the device’s compact size reduces the requirement for
water bath size and, in turn, reduces the filling, degassing,
heating, and emptying times required. These two aspects
of the previous system likely have the most significant
impact on the time and training required to set up an
experiment.
Automating and providing a convenient user interface
for the driving of the six transducers has yet to be solved
and is the subject of future work. Doing so would allow
for the six transducers to expose the six target areas of the
Opticell in a concurrent, interlaced, or sequential manner
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as well as allow for per-transducer driving conditions.
Concurrent exposure is potentially possible given the
directivity of the transducers (Fig. 4). This scheme would
reduce further the total time required to perform an
experiment by reducing the time to perform sonication
from 7 to 1.5 min per Opticell as well as avoid differences
in the conditions between exposures due to temporal
changes.
There are commercial systems as well which aim to
make performing sonoporation studies easier. For exam-
ple, the Sonidel SP100 (Sonidel Ltd., Dublin, Ireland) is a
sonoporator which is commercially available. This device
consists of a free ultrasound transducer, driving electron-
ics, and easy-to-use interface. While this device been used
in a number of sonoporation studies, it often appears to
be used with “modification” [17, 19]. The acoustic con-
ditions at the cells is not necessarily ensured in its stock
configuration due to the use of a hand-held ultrasound
transducer. That is, this sonoporator still requires an addi-
tional experimental apparatus to ensure consistent ultra-
sound exposure between experiments. Hence, this system
fails to address the same issues as the device presented
here.
Unfortunately, Opticells have recently been discontin-
ued. However, the concept of a device for performing
sonoporation on adherent cell cultures which minimizes
operator expertise could certainly be adapted for a suit-
able alternative cell culture system if one were to become
available.
Conclusions
The design of a prototype device to minimize the time
and expertise required to perform in vitro sonoporation
onmonolayer cell cultures was devised, characterized, and
experimentally validated. A preliminary study of sonopo-
ration of SiHa cells under mild hyperthermic conditions
did not show a significant effect on transfection efficiency
or viability over normal conditions. The prototype device
has been shown to be effective for use in sonoporation
studies and will provide a reduction in the time and train-
ing required to perform these types of studies in the
future.
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